APA (7th ed.) Citation

Moon, Y. W., Kim, S. K., Lee, K. S., Lee, M. H., Park, Y. H., Park, K. H., . . . Im, S. (2023). Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies. Cancer research and treatment, 55(3), 766-777. https://doi.org/10.4143/crt.2022.987

Chicago Style (17th ed.) Citation

Moon, Yong Wha, et al. "Eflapegrastim Versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies." Cancer Research and Treatment 55, no. 3 (2023): 766-777. https://doi.org/10.4143/crt.2022.987.

MLA (9th ed.) Citation

Moon, Yong Wha, et al. "Eflapegrastim Versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies." Cancer Research and Treatment, vol. 55, no. 3, 2023, pp. 766-777, https://doi.org/10.4143/crt.2022.987.